What is Eszopiclone?
Eszopiclone is a nonbenzodiazepine hypnotic medication (a "Z-drug") approved for treating both sleep onset and sleep maintenance insomnia in adults, with no short-term restrictions on duration of use. 1
Drug Classification and Mechanism
Eszopiclone is the S-enantiomer of racemic zopiclone, belonging to the cyclopyrrolone class of hypnotics 1. Its chemical structure is distinct from benzodiazepines, barbiturates, and other hypnotic classes. The drug works by binding to GABA-receptor complexes at sites located close to or allosterically coupled to benzodiazepine receptors 1. Unlike traditional benzodiazepines, eszopiclone demonstrates greater selectivity for certain GABA(A) receptor subunits 2.
Pharmacokinetics
The drug exhibits predictable absorption and elimination characteristics:
- Absorption: Rapidly absorbed with peak plasma concentration (Tmax) at approximately 1 hour 1
- Half-life: Approximately 6 hours in adults; extends to 9 hours in elderly patients (≥65 years) 1
- Protein binding: Weakly bound (52-59%), suggesting minimal drug-drug interactions from protein displacement 1
- Metabolism: Extensively metabolized via CYP3A4 and CYP2E1 pathways through oxidation and demethylation 1
- Excretion: Less than 10% excreted unchanged in urine 1
Important note: Taking eszopiclone with or immediately after a high-fat meal reduces Cmax by 21% and delays Tmax by 1 hour, potentially reducing sleep onset effects 1.
Clinical Efficacy
Guideline-Based Recommendations
The American Academy of Sleep Medicine (2017) suggests using eszopiclone for treating both sleep onset AND sleep maintenance insomnia in adults 2. This recommendation applies to 2 mg and 3 mg doses 2.
The American College of Physicians (2016) identified eszopiclone as one of only three medications (along with zolpidem and suvorexant) with moderate-strength evidence for improving short-term global and sleep outcomes 3.
Quantified Benefits
Based on meta-analytic data, eszopiclone produces:
- Sleep onset latency: 12-minute reduction compared to placebo 3
- Wake after sleep onset: 17-minute reduction 3
- Total sleep time: 28-minute increase 3
- Sleep maintenance: 10-14 minute reduction in wake time after sleep onset (specific to eszopiclone data) 2
These improvements are statistically significant but represent small-to-moderate absolute effect sizes 3.
Dosing Considerations
Standard adult dose: 2-3 mg at bedtime 2
Elderly patients (≥65 years): Maximum dose should not exceed 2 mg due to 41% increase in drug exposure and prolonged elimination 1
Hepatic impairment: No adjustment needed for mild-to-moderate impairment; severely impaired patients require dose reduction due to 2-fold increase in exposure 1
Renal impairment: No dose adjustment necessary 1
Safety Profile
Common Adverse Events
The most frequently reported side effects include 2:
- Unpleasant/bitter taste: 17-34% (dose-dependent; 7% increased risk vs placebo) - most distinctive side effect
- Dry mouth: 6% increased risk vs placebo
- Somnolence: 4-9%
- Dizziness: 3-5%
- Headache: No significant difference from placebo
Serious Safety Concerns
The FDA warns about 3:
- Cognitive and behavioral changes including impaired driving ability
- Next-morning impairment (drugs remain at levels affecting morning activities)
- Complex sleep behaviors (sleep-driving, sleep-walking)
- Dose reduction advised in women and elderly/debilitated adults
Long-term Risks
Observational studies suggest associations with 3:
- Increased risk of dementia
- Fractures and major injuries
- Possible increased cancer risk (noted in some analyses)
Critical caveat: Most trials enrolled carefully selected patients meeting stringent criteria, so real-world adverse event profiles may differ 3.
Tolerance and Dependence
- No tolerance observed during 12 months of continuous treatment 2
- Minimal rebound insomnia: No significant changes in sleep onset latency or wake time after sleep onset during first 3 nights post-discontinuation 3
- Withdrawal symptoms: Some studies reported new adverse events (anxiety, abnormal dreams, nausea) following discontinuation of 2-3 mg doses 2
- Abuse potential: At supratherapeutic doses (6-12 mg), produces euphoria similar to diazepam 20 mg in individuals with benzodiazepine addiction history 2
Duration of Use
Unlike most hypnotics, eszopiclone has no FDA-mandated short-term restriction 2. It is the first sedative-hypnotic approved for long-term use without duration limitations 4. Studies demonstrate sustained efficacy up to 6-12 months without tolerance development 2, 5.
Clinical Context
Eszopiclone is indicated for chronic insomnia disorder, defined as sleep problems occurring ≥3 nights per week, persisting ≥3 months, and causing clinically significant distress or daytime dysfunction 3. The medication has been studied in both primary insomnia and insomnia comorbid with depression, anxiety, chronic pain, and other conditions 3, 5.
Important limitation: Most patients at study end continued to have symptoms exceeding enrollment thresholds, indicating medications typically do not achieve complete remission 3.